Pharmaceutical

Actimed plans trials to treat muscle wasting syndrome in cancer patients

The company aims to start two trials in H1 2024 based on its current timeline, depending on if it closes its Series B round soon.

Jul 13, 2023 - 20:00
Actimed plans trials to treat muscle wasting syndrome in cancer patients
The company aims to start two trials in H1 2024 based on its current timeline, depending on if it closes its Series B round soon.
Read the original article

Tags:

Previous Article

FDA greenlights first over-the-counter birth control pill

Next Article

NVIDIA invests $50m in AI-enabled drug discovery

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

‘We fail people’: New data on disparities in Medicaid access to opioid addiction treatment

‘We fail people’: New data on disparities in Medicaid a...

Jun 24, 2023

Simcere Zaiming and TargetRx agree TGRX-326 commercial rights

Simcere Zaiming and TargetRx agree TGRX-326 commercial ...

Sep 4, 2024

STAT+: Medicare wants to improve Alzheimer’s care, but sidesteps drug prices

STAT+: Medicare wants to improve Alzheimer’s care, but ...

Aug 1, 2023